KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm. 2025;39(4):206-212 / www.klinickafarmakologie.cz 212 HLAVNÍ TÉMA TDM jako nástroj pro farmakogenetické profilování pacientů: kazuistika fenokonverze 11. Světlík S, Hronová K, Slanař O. Fenotypizace enzymů podílejících se na metabolismu léčiv. Čes slov Farm. 2012;61(3):115-26. 12. Bousman ChA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clinical Pharmacology and Therapeutics. 2023;114(1):51-68. 13. Porcelli S, Fabbri Ch, Serretti A. Meta-Analysis of Serotonin Transporter Gene Promoter Polymorphism (5-HTTLPR) Association with Antidepressant Efficacy. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology. 2012;22(4):239-258. 14. Hahn M, Müller DJ, Roll SC. Frequencies of Genetic Polymorphisms of Clinically Relevant Gene-Drug Pairs in a German Psychiatric Inpatient Population. Pharmacopsychiatry. 2021;54(2):81-89. 15. Sládková Kavínová H, Dorofeev A. Farmakogenetické vyšetření v psychiatrické praxi v ČR. Acta Medicinae. 2023;16:36-39. 16. Tašková I. Terapeutické monitorování psychofarmak z pohledu klinického farmaceuta: doporučení versus praxe. Remedia. 2020;30:650-656. 17. Scherf-Clavel M, Frantz A, Eckert A, et al. Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study. Int J Clin Pharm. 2023;45(5): 1107-1117. 18. European Medicines Agency. Guideline on the investigation of drug interactions [online]. 2012 [cit. 17. 4. 2025]. Dostupné z: https://www.ema.europa.eu/. 19. The Flockhart Cytochrome P450 Drug-Drug Interaction Table. Updated 2021. [online]. Dostupné z: https://drug-interactions.medicine.iu.edu/ 20. Center for Drug Evaluation, and Research. 2025. “For Healthcare Professionals.” U.S. Food and Drug Administration. FDA. [online]. June 27, 2025. Dostupné z: https://www. fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems. 21. University of Florida Health. CYP2D6 phenoconversion calculator [online]. Přístup 31. 3. 2025. Dostupné z: https:// precisionmedicine.ufhealth.org/. 22. Cicali EJ, Elchynski AL, Cook KJ, et al. How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial. Clin Pharmacol Ther. 2021;110(3):677-687. 23. Bloch MH, McGuire J, Landeros-Weisenberger A, et al. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry. 2010;15(8):850-855. 24. Schulz M, Schmoldt A, Andresen-Streichert H, et al. Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics. Crit Care. 2020;24:195. 25. Chen R, Shen K, Hu P. Single- and multiple-dose pharmacokinetics and tolerability of a paroxetine controlled-release tablet in healthy Chinese subjects. Int J Clin Pharmacol Ther. 2017;55(3):231-236. 26. DrugBank Online. Paroxetin [online]. Edmonton (AB): DrugBank; 2024 [cit. 19. 4. 2025]. Dostupné z: https://go.drugbank. com/drugs/DB00715. 27. Remood 20 mg tablety. Souhrn údajů o přípravku (SPC) [online]. Praha: Medicom International; [cit. 19. 4. 2025]. Dostupné z: https://www.sukl.cz/. 28. Paroxetine: Drug information [online]. UpToDate. Waltham (MA): UpToDate, Inc.; 2024 [cit. 19. 4. 2025]. Dostupné z: https://www.uptodate.com/. 29. Hilleret H, Voirol P, Bovier P, et al. Very long half-life of paroxetine following intoxication in an extensive cytochrome P4502D6 metabolizer. Ther Drug Monit. 2002;24(4):567-569. 30. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, et al. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos. 2003;31(3):289-293. 31. Saito M, Yasui-Furukori N, Nakagami T, et al. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. J Clin Psychopharmacol. 2005;25(6):527-532. 32. Hahn M, Roll SC. The role of phenoconversion in the pharmacogenetics of psychiatric medication. Pharmacogenomics. 2023;24(9):485-487.
RkJQdWJsaXNoZXIy NDA4Mjc=